Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. CDC Says Flu Strain Resistant To Tamiflu, Leaving Only Relenza

This article was originally published in PharmAsia News

Executive Summary

U.S. authorities have found one of the two main anti-influenza drugs has become ineffective in treating a common flu strain in the United States, leaving only Australia-developed Relenza (zanamivir) as an effective treatment. The U.S. Centers for Disease Control and Prevention said the H5N1 strain circulating across the United States has become resistant to Roche's Tamiflu (oseltamivir). The CDC urged physicians to switch to Relenza, developed by Biota and marketed in the United States by GlaxoSmithKline, or prescribe Tamiflu in combination with ramantadine. (Click here for more)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts